KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Intangibles (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Intangibles for 16 consecutive years, with $247.3 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Intangibles fell 11.55% year-over-year to $247.3 million, compared with a TTM value of $247.3 million through Mar 2025, down 11.55%, and an annual FY2024 reading of $255.3 million, down 13.38% over the prior year.
  • Intangibles was $247.3 million for Q1 2025 at Biomarin Pharmaceutical, down from $255.3 million in the prior quarter.
  • Across five years, Intangibles topped out at $388.7 million in Q4 2021 and bottomed at $247.3 million in Q1 2025.
  • Average Intangibles over 5 years is $315.7 million, with a median of $302.5 million recorded in 2023.
  • The sharpest move saw Intangibles fell 6.86% in 2021, then fell 13.38% in 2024.
  • Year by year, Intangibles stood at $388.7 million in 2021, then fell by 3.71% to $374.3 million in 2022, then fell by 21.26% to $294.7 million in 2023, then decreased by 13.38% to $255.3 million in 2024, then dropped by 3.11% to $247.3 million in 2025.
  • Business Quant data shows Intangibles for BMRN at $247.3 million in Q1 2025, $255.3 million in Q4 2024, and $279.7 million in Q1 2024.